These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 25785210)
1. Hyperhemolysis Syndrome without Underlying Hematologic Disease. Eberly LA; Osman D; Collins NP Case Rep Hematol; 2015; 2015():180526. PubMed ID: 25785210 [TBL] [Abstract][Full Text] [Related]
2. Hyperhemolysis syndrome in anemia of chronic disease. Darabi K; Dzik S Transfusion; 2005 Dec; 45(12):1930-3. PubMed ID: 16371046 [TBL] [Abstract][Full Text] [Related]
3. Delayed hemolytic transfusion reaction/hyperhemolysis syndrome in children with sickle cell disease. Talano JA; Hillery CA; Gottschall JL; Baylerian DM; Scott JP Pediatrics; 2003 Jun; 111(6 Pt 1):e661-5. PubMed ID: 12777582 [TBL] [Abstract][Full Text] [Related]
4. Hyperhemolysis syndrome in a patient without a hemoglobinopathy, unresponsive to treatment with eculizumab. Gupta S; Fenves A; Nance ST; Sykes DB; Dzik WS Transfusion; 2015 Mar; 55(3):623-8. PubMed ID: 25257194 [TBL] [Abstract][Full Text] [Related]
5. An Unusual Case of Delayed Hemolytic Transfusion Reaction With Hyperhemolysis Syndrome Due to Anti-Jk El Alaoui K; Benghiat FS; Colard M J Hematol; 2022 Apr; 11(2):66-70. PubMed ID: 35573755 [TBL] [Abstract][Full Text] [Related]
6. Successful Outcome of Hyperhemolysis in Sickle Cell Disease following Multiple Lines of Treatment: The Role of Complement Inhibition. Vlachaki E; Gavriilaki E; Kafantari K; Adamidou D; Tsitsikas D; Chasapopoulou E; Anagnostopoulos A; Tsapas A Hemoglobin; 2018; 42(5-6):339-341. PubMed ID: 30626228 [TBL] [Abstract][Full Text] [Related]
7. Anti-N and anti-Do Unnikrishnan A; Pelletier JPR; Bari S; Zumberg M; Shahmohamadi A; Spiess BD; Michael MJ; Harris N; Harrell D; Mandernach MW Transfusion; 2019 Jun; 59(6):1907-1910. PubMed ID: 30768787 [TBL] [Abstract][Full Text] [Related]
8. Rare antibody-associated hemolytic transfusion reaction and transfusion-related acute lung injury: a case report. Beck TN; Young NG; Erickson ML; Prats I BMC Surg; 2017 Apr; 17(1):48. PubMed ID: 28441942 [TBL] [Abstract][Full Text] [Related]
10. Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions. Aygun B; Padmanabhan S; Paley C; Chandrasekaran V Transfusion; 2002 Jan; 42(1):37-43. PubMed ID: 11896310 [TBL] [Abstract][Full Text] [Related]
11. Hyperhemolysis syndrome in patients with sickle cell anemia: report of three cases. Santos B; Portugal R; Nogueira C; Loureiro M Transfusion; 2015 Jun; 55(6 Pt 2):1394-8. PubMed ID: 25677578 [TBL] [Abstract][Full Text] [Related]
12. Delayed hemolytic transfusion reaction due to anti-Jk(a). Vucelic D; Savic N; Djordjevic R Acta Chir Iugosl; 2005; 52(3):111-5. PubMed ID: 16813007 [TBL] [Abstract][Full Text] [Related]
13. Posttransfusion hyperhemolysis is arrested by targeting macrophage activation with novel use of Tocilizumab. Lee LE; Beeler BW; Graham BC; Cap AP; Win N; Chen F Transfusion; 2020 Jan; 60(1):30-35. PubMed ID: 31642065 [TBL] [Abstract][Full Text] [Related]
14. Delayed hemolytic transfusion reaction with hyperhemolysis after first red blood cell transfusion in child with beta-thalassemia: challenges in treatment. Hannema SE; Brand A; van Meurs A; Smiers FJ Transfusion; 2010 Feb; 50(2):429-32. PubMed ID: 19788508 [TBL] [Abstract][Full Text] [Related]
15. Acute Hyperhemolysis Syndrome in a Patient with Known Sickle Cell Anemia Refractory to Steroids and IVIG Treated with Tocilizumab and Erythropoietin: A Case Report and Review of Literature. Menakuru SR; Priscu A; Dhillon V; Salih A Hematol Rep; 2022 Jul; 14(3):235-239. PubMed ID: 35893156 [TBL] [Abstract][Full Text] [Related]